AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.
The company's Med Tech segment, which includes platforms such as Auryon and NanoKnife, surged 13% to $35.7 million, underscoring a strategic pivot toward technology-driven products with stronger profitability.
Key drivers included an 18.6% increase in sales of the Auryon atherectomy system, used for treating peripheral artery disease, and a 22.2% jump for the NanoKnife irreversible electroporation platform, which targets cancer treatments.
Gross margin expanded by 170 basis points to 56.4%, benefiting from the favorable product mix, manufacturing efficiencies, and the shift to a distributor model in France.
Adjusted EBITDA nearly doubled to $5.9 million from $3.1 million a year earlier, reflecting operational leverage as Med Tech gains offset softer areas.
During the period under review, AngioDynamics generated $4.7 million in operating cash flow and ended the quarter debt-free with $41.6 million in cash and equivalents.
On the regulatory front, the company secured two FDA Investigational Device Exemption approvals for the APEX-Return and PAVE studies, paving the way for expanded indications in its mechanical thrombectomy portfolio.